Skip to main content
TipRanks
Go Ultimate75% OFF

TOMI Environmental Solutions (TOMZ) Q3 2026 Earnings Report

207 Followers

TOMZ Q3 2026 EPS Results

Actual EPS
$0.00
Consensus EPS
$0.00
Beat/Miss
Met expectations
One Year Ago EPS
-$0.06

TOMZ Q3 2026 Revenue Results

Actual Revenue
$2.49M
Expected Revenue
$3.01M
Beat/Miss
Missed by -$521.20K
YoY Revenue Growth
+23.92%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
TOMZ Upcoming Earnings

TOMI Environmental Solutions's next earnings date is estimated for April 6, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

TOMZ Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-7.00%|
Earnings Call Sentiment|Positive

The call was strongly constructive, with highlights significantly outweighing the lowlights. Management reported sequential and year-over-year revenue growth, a return to positive operating income, lower operating expenses, strong product and mobile-equipment demand, expanding backlog and pipeline, and progress across life sciences, defense, corporate services and food safety. The main challenges were unresolved accounting treatment for convertible notes, limited service-revenue growth from a customer production change, working-capital needs, and regulatory requirements that continue to delay broader food safety and medical sterilization commercialization.

Company Guidance

Management remains focused on its goal of $12 million in sales for 2026, with a full pipeline of $35 million, an active pipeline of $8.5 million to $10 million, current standing $9.3 million revenue plus open book sales for 2026, and expectations to receive approximately $5 million in purchase orders before year-end; some or all of the prospective orders are expected before year-end in a range of approximately $960,000 to $1.7 million, while 2 custom engineered systems are scheduled for installation in February and April 2027. The company expects shareholder equity at September 30, 2026, to be in a range of $3 million to $4 million, expects IHP deployment service revenue to increase going forward, expects gross profit to be increasing going forward, and anticipates profitability going forward.

  • Sequential Revenue Growth and Q3 Revenue IncreaseTOMI delivered another consecutive quarter of sequential revenue growth. Revenue increased approximately 36% from Q1 to Q2 and a further 11% from Q2 to Q3, with Q3 revenue approximately 51% above Q1. Q3 2026 revenue was approximately $2.49 million, up about 24% from $2.01 million in Q3 2025 and 11% from $2.25 million in Q2 2026.
  • Return to Positive Operating IncomeThe company generated approximately $30,000 of positive operating income in Q3, its first positive quarterly operating result since Q3 2024, compared with operating losses of approximately $321,000 in Q3 2025 and $244,000 in Q2 2026.
  • Product Revenue and U.S. Revenue GrowthProduct sales increased approximately 30% year-over-year to approximately $2.08 million from approximately $1.6 million. U.S. revenue increased 50% to approximately $1.92 million.
  • Nine-Month Revenue and Product GrowthFor the first nine months of 2026, total revenue increased 38% to approximately $6.39 million, including 61% growth in product revenue.
  • Higher Gross Profit and Lower Operating ExpensesGross profit increased 19% year-over-year to approximately $1.47 million from approximately $1.23 million. Operating expenses declined 7% to approximately $1.44 million from approximately $1.55 million, led by a significant reduction in general and administrative expenses, despite continued elevated professional and consulting costs associated with strategic and financing activities.
  • Backlog and Revenue VisibilityThe sales order backlog was approximately $2.5 million as of September 30 and subsequently increased to approximately $2.8 million. Management said 2026 is expected to end with growth across each department, providing good visibility into near-term revenue.
  • BIT Solutions and Mobile Equipment MomentumDelivered BIT Solutions sales year-to-date plus open orders had already surpassed BIT Solution sales for all of the prior year, with two months still remaining. Mobile equipment year-to-date sales plus open orders were above the prior year's full-year total by almost 107%, while service continued to trend higher.
  • Razor/Razor-Blade Model and Applicator StrategyTOMI is continuing its razor/razor-blade model, with the applicator now a core component. Management stated that the applicator generates revenue and margin while supporting recurring BIT Solution demand over time, and has a shorter sales cycle than full capital equipment.
  • Sales Pipeline and Active OpportunitiesThe current sales opportunity pipeline has a projected value of approximately $35 million, including opportunities from proposals through negotiations and purchasing. The active, late-stage pipeline was described as approximately $8.5 million to $10 million, with high-probability opportunities within the approximately $12 million mark. The pipeline includes integrated system, hybrid and Custom Engineered System opportunities.
  • 2026 Purchase Order ExpectationsManagement expects to receive approximately $5 million in purchase orders before year-end across several accounts. The expected orders include mobile equipment and two Custom Engineered Systems, with some deliveries planned for the first quarter and second quarter of 2027.
  • Major Customer Expansion and European Regulatory AcceptanceA nearly $1 million project to add applicators to proprietary machine lines at a major multinational health care manufacturer is underway, and the customer is expanding into additional facilities after TOMI received European Union regulatory acceptances.
  • Global Defense and Corporate Service ExpansionTOMI expanded its defense-sector presence following approvals from defense contractors in Korea and defense agencies in Canada, and provided one of the two agencies with systems ready for deployment. Corporate Service engagements include Integra Pharma, Catalent, Cleveland Clinic and LFB USA, with on-site support provided approximately four times a month, including at the CDC in Atlanta.
  • Customer and Partner ExpansionSteraMist iHP activity increased across the Americas in life sciences, food safety and health care. TOMI added partners in Mexico and Argentina and completed further business in India and the European Union. A leading global eye health customer placed an additional equipment order in Q3; combined revenue for its two sites is approximately $750,000, and the customer has a recurring BIT Solution agreement.
  • Food Safety Validation and Market DevelopmentAn independent laboratory study showed that SteraMist iHP reduced a specific type of Listeria by an average of greater than 7 logs on flat surfaces, at or below the laboratory detection limit. TOMI is pursuing food safety opportunities in meat, ready-to-eat products, dairy, infant formula, nutritional products and poultry, and management stated that several food manufacturers are using repeatable protocols that support ongoing product consumption.
  • Food Safety Customer and Regulatory ProgressTOMI continues work with Nestle, Danone and another nutritional company on international registrations and FDA food contact notifications. Nestle added additional locations, further registrations were submitted worldwide, and TOMI engaged food safety specialist Josh Hasty, PhD to support its initiatives. TOMI also made progress toward NSF certification for biosafety cabinet decontamination and filed an FSIS new technology notification.
  • Life Sciences and Health Care AdoptionLife Sciences remains TOMI's largest division and core business. Established customers continue to expand their use of SteraMist iHP, and special pathogen units saw growing adoption through the first half of 2026, including delivery of the first NV+ system to one of these units. TOMI said it is prepared to support increased requests with deployable systems, an on-site service team and a global partner network.
  • Working Capital Improvement and Financing ActionsWorking capital increased to approximately $1.95 million from $1.02 million at the end of 2025. Management is discussing additional credit facilities or a PIPE-type offering and said customer deposits, which can be approximately 50% on large accounts, help the company manage capital requirements.
  • Potential Profitability ImprovementManagement said higher revenue is expected to increase gross profit, operating expenses are being tightened, and interest expense is expected to decline following conversion of note holders. The CFO said the company is anticipating improved profitability going forward.
  • Strategic Project and Future Installation ScheduleThe current 2026 delivered sales plus open orders were described as approximately $9.3 million, separate from the approximately $5 million of additional purchase orders expected before year-end. Two large-scale Custom Engineered Systems are scheduled for installation in February and April 2027.

TOMZ Earnings History

TOMZ earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Apr 06, 20272026 (Q4)0.09--0.12――
Nov 12, 20262026 (Q3)0.000.00-0.06100.00% (+0.06)
Aug 14, 20262026 (Q2)-0.11-0.05-0.1872.22% (+0.13)
May 08, 20262026 (Q1)―--0.01―
Mar 31, 20262025 (Q4)-0.12-0.12-0.03-300.00% (-0.09)
Nov 14, 20252025 (Q3)-0.03-0.060―
Aug 14, 20252025 (Q2)-0.09-0.180―
May 08, 20252025 (Q1)―-0.01-0.2195.24% (+0.20)
Apr 14, 20252024 (Q4)-0.15-0.03-0.2185.71% (+0.18)
Oct 30, 20242024 (Q3)0.000.00-0.15100.00% (+0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed